Evaluation of anti-CMV T cellular immunity using an IGRA test (Quantiferon-CMV test) in kidney transplant recipients and hemodialysis patients, comparison to control patients.
Cytomegalovirus (CMV) infection is a common opportunistic complication after kidney transplantation (KT). It has been associated with high morbidity and mortality in kidney transplant recipients (KTR). Its actual management is only based on the humoral immunity : the main risk factor for CMV infection after KT is the association of a seropositive donor and a seronegative recipient (so-called "D+/R- mismatch"). However several studies have highlighted the essential role of cellular immunity to control CMV infection. The Quantiferon-CMV (QF-CMV) is an IGRA test (Interferon Gamma Releasing Assay) which evaluates T CD8 lymphocytes production of Interferon Gamma (IFNy) exposed to CMV antigens. Some studies have shown the possible interest of the QF-CMV in predicting CMV infection after antiviral prophylaxis discontinuation or when CMV viremia is detected. However some limits have been underlined. First its positivity threshold hasn't been approved in KTR. Hemodialysis patients (HP) called to receive a renal allograft also suffered from altered immunity. No study has directly compared the QF-CMV value in KTR, HP and control patients. That's why we propose evaluating the expression of basal cellular immunity against CMV (far from any active infection) in KTR and HP using the QF-CMV and comparing it to control patients population (not suffering from kidney dysfunction or immunosuppression).
Study Type
OBSERVATIONAL
Enrollment
60
Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
Chu Grenoble Alpes
Grenoble, France
Quantification of anti-CMV T cellular immunity in kidney transplant recipients, hemodialysis patients and control patients.
Quantification of IFNy level producted by T cells exposed to CMV antigens using a Quantiferon-CMV test in kidney transplant recipients, hemodialysis patients and control patients.
Time frame: Single measurement at Day 0 of patient inclusion
Quantification of patient cellular immunity.
Quantification of lymphocytes subpopulations.
Time frame: Single measurement at Day 0 of patient inclusion
Evaluation of kidney transplant recipient exposure to immunosuppressive therapy.
Assessment of last tacrolimus trough concentration.
Time frame: Single collection at Day 0 of patient inclusion
Estimation of renal function.
Evaluation of estimated glomerular filtration rate by plasmatic creatinin dosage using CKD-EPI estimate.
Time frame: Single measurement at Day 0 of patient inclusion
Assessment of CMV donor humoral immunity in kidney transplant recipients.
Assessment of donor CMV serology.
Time frame: Single collection at Day 0 of patient inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.